A Population Based Study of Incidence of Post Kidney Transplant Malignancies
1Department of Nephrology & Transplantation, Beaumont Hospital Dublin, Royal College of Surgeons Ireland, Dublin, Ireland
2Department of Otolaryngology, Head and Neck Surgery, Beaumont Hospital, Dublin, Ireland
3National Cancer Registry Ireland, Cork, Ireland
4Department of Oncology, Beaumont Hospital, Dublin, Ireland.
Meeting: 2018 American Transplant Congress
Abstract number: B349
Keywords: Immunosuppression, Malignancy
Session Information
Session Name: Poster Session B: PTLD/Malignancies: All Topics
Session Type: Poster Session
Date: Sunday, June 3, 2018
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Hall 4EF
Introduction
We aimed to report national standardised incidence for malignancy post transplant compared to the general population stratified by solid organ categories. In this study we report our findings for kidney transplantation on behalf of the Irish post transplant malignancy working group.
Methods
The national kidney transplant registry was linked with the national Irish Cancer Registry to capture episodes of malignancy over follow up. Standardised incidence ratios (SIRs) were calculated in comparison to the general population using the Irish census data as the denominator, and using ICD10 coding for malignancy diagnosis. Transplant recipients were considered at risk beginning at transplantation or start of cancer registry coverage on 01/01/1994. Follow-up ended at death or at the cancer registry censor date 31/12/2014. Only the first cancer diagnosis at each site is considered when calculating SIRs.
Results
See table 1 for SIRs for various malignancies post kidney transplant.
Conclusions
This study provides national data on cancer incidence following kidney transplantation in comparison to the general population in Ireland. These increased rates of cancer in transplant patients emphasise the need for careful long-term management.
Kidney Transplant (N=3825) | |
SIRs (95% CI) | |
Invasive Cancers excluding Non-Melanoma Skin Cancer (NMSC) | 1.69(1.5-1.89) |
By grouping | |
Head and Neck | 9.06(8.31-9.86) |
Upper GI | 1.08(0.52-1.99) |
Colorectal | 1.45(1-2.02) |
Hepatobiliary | 1.23(0.56-2.33) |
Trachea, bronchus and lung | 1.45(0.99-2.06) |
Female genital | 1.78(1.02-2.89) |
Male genital | 0.9(0.63-1.25) |
Urinary | 3.85(2.75-5.25) |
Urology | 1.53(1.2-1.92) |
All skin | 10.07(9.36-10.81) |
Melanoma | 2.19(1.25-3.56) |
NMSC | 10.79(10.03-11.59) |
NMSC – BCC | 8.33(7.58-9.12) |
NMSC – SCC | 27.6(25.31-30.04) |
Brain and central nervous system | 1.1(0.3-2.81) |
Haematology (blood and lymph cancers) | 3.25(2.47-4.21) |
Non-Hodgkin's lymphoma | 6.48(4.72-8.67) |
Leukaemia | 0.42(0.05-1.52) |
CITATION INFORMATION: Sexton D., O'Neill J., O'Kelly P., Murray S., Deady S., O'Leary E., Morris P., Conlon P. A Population Based Study of Incidence of Post Kidney Transplant Malignancies Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:
Sexton D, O'Neill J, O'Kelly P, Murray S, Deady S, O'Leary E, Morris P, Conlon P. A Population Based Study of Incidence of Post Kidney Transplant Malignancies [abstract]. https://atcmeetingabstracts.com/abstract/a-population-based-study-of-incidence-of-post-kidney-transplant-malignancies/. Accessed November 23, 2024.« Back to 2018 American Transplant Congress